Pacira BioSciencesPCRX
PCRX
About: Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Employees: 712
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
26% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 68
17% more call options, than puts
Call options by funds: $6.72M | Put options by funds: $5.74M
2.07% less ownership
Funds ownership: 112.65% [Q2] → 110.58% (-2.07%) [Q3]
15% less funds holding
Funds holding: 278 [Q2] → 236 (-42) [Q3]
46% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 91
49% less capital invested
Capital invested by funds: $1.5B [Q2] → $768M (-$732M) [Q3]
75% less funds holding in top 10
Funds holding in top 10: 4 [Q2] → 1 (-3) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$16
16%
downside
Avg. target
$22
18%
upside
High target
$39
105%
upside
5 analyst ratings
3 positive
60%
2 neutral
40%
0 negative
0%
HC Wainwright & Co. Oren Livnat 50% 1-year accuracy 23 / 46 met price target | 105%upside $39 | Buy Reiterated | 4 Dec 2024 |
Barclays Balaji Prasad 48% 1-year accuracy 21 / 44 met price target | 10%downside $17 | Equal-Weight Maintained | 12 Nov 2024 |
Needham Serge Belanger 40% 1-year accuracy 50 / 126 met price target | 16%upside $22 | Buy Reiterated | 8 Nov 2024 |
RBC Capital Gregory Renza 40% 1-year accuracy 32 / 81 met price target | 16%downside $16 | Sector Perform Maintained | 7 Nov 2024 |
Jefferies Glen Santangelo 67% 1-year accuracy 4 / 6 met price target | 5%downside $18 | Buy Maintained | 24 Sept 2024 |
Financial journalist opinion
Based on 25 articles about PCRX published over the past 30 days
Neutral
Accesswire
1 day ago
An Investigation Has Commenced on Behalf of Pacira BioSciences, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your PCRX Losses.
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Neutral
Accesswire
2 days ago
Pacira BioSciences, Inc. (PCRX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Positive
Zacks Investment Research
3 days ago
Here's Why Pacira (PCRX) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Neutral
Accesswire
3 days ago
Levi & Korsinsky Reminds Shareholders of an Investigation into Pacira BioSciences, Inc. (PCRX) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Neutral
Accesswire
4 days ago
Lost Money on Pacira BioSciences, Inc.(PCRX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Neutral
Accesswire
5 days ago
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pacira BioSciences, Inc. (PCRX) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Neutral
Accesswire
1 week ago
Pacira BioSciences, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Pacira BioSciences, Inc. (PCRX)
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Neutral
Accesswire
1 week ago
Pacira BioSciences, Inc. (PCRX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Neutral
PRNewsWire
1 week ago
DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.
Expresses Conviction in Pacira's IP and Belief that Shares are Significantly Undervalued Urges Pacira to Immediately Commence Stock Tender Offer with Cash on Hand MIAMI , Dec. 11, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC (together with its affiliates, "DOMA"), which beneficially owns approximately 4.14% of the outstanding shares of Common Stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company"), today announced that it intends to nominate four highly-qualified, independent director candidates at the Company's 2025 annual meeting of stockholders, and stated that it has hired Olshan Frome Wolosky LLP as counsel to represent it in its dealings with the Company. DOMA further stated that it believes strongly in the value of the Company's intellectual property and that the Company's stock is grossly undervalued and urged the Company to immediately commence a stock tender offer for 10 million shares using its substantial cash on hand, and then execute its already-approved $150 million buyback program using the Company's healthy and growing free cash flow.
Neutral
Accesswire
1 week ago
Pacira BioSciences, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - PCRX
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Charts implemented using Lightweight Charts™